Harvard Bioscience, Inc. (NASDAQ: HBIO) Executes Reverse Stock Split

Company Overview - Harvard Bioscience, Inc. (NASDAQ: HBIO) is a significant entity in the life science research tools sector, providing essential equipment and solutions for scientific research, thereby supporting advancements in biology and medicine [1] - The company competes with other firms in the life sciences industry, focusing on innovation and strategic decisions to maintain its market position [1] Recent Corporate Actions - On March 16, 2026, HBIO executed a reverse stock split at a 10-for-1 ratio, a move approved by the board and stockholders, aimed at increasing the stock's per-share trading price [2] - The reverse stock split took legal effect on March 13, 2026, at 4:30 p.m. Eastern Time, with trading on a post-split adjusted basis commencing on March 16, 2026 [3] Stock Performance - Currently, HBIO's stock is priced at $0.47, reflecting a 4.15% decrease with a $0.02 change, and has fluctuated between $0.45 and $0.49 recently [3] - Over the past year, the stock reached a high of $9.45 and a low of $0.45, indicating significant volatility [3] Market Metrics - HBIO's market capitalization is approximately $21.17 million, with a trading volume of 479,292 shares, highlighting the company's market activity and investor interest [4]